世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ペプチド・オリゴヌクレオチドCDMOの世界市場成長(現状と展望) 2023-2029


Global Peptide and Oligonucleotide CDMO Market Growth (Status and Outlook) 2023-2029

弊社(LP Info Research)の最新調査によると、世界のペプチド・オリゴヌクレオチドCDMO市場規模は2022年に1億5,652万米ドルとなった。川下市場での需要拡大とCOVID-19やロシア・ウクライナ戦争の影響からの回復... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年8月2日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
111 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

弊社(LP Info Research)の最新調査によると、世界のペプチド・オリゴヌクレオチドCDMO市場規模は2022年に1億5,652万米ドルとなった。川下市場での需要拡大とCOVID-19やロシア・ウクライナ戦争の影響からの回復により、ペプチド・オリゴヌクレオチドCDMOはレビュー期間中のCAGR10.4%で2029年までに3億1234万米ドルの再調整規模になると予測されている。
この調査レポートは、世界のペプチドおよびオリゴヌクレオチドCDMO市場の成長の可能性を明らかにしています。COVID-19やロシア・ウクライナ戦争の影響からの回復に伴い、ペプチド・オリゴヌクレオチドCDMOは今後の市場でも安定した成長が見込まれる。しかし、ペプチド・オリゴヌクレオチドCDMOの普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場関係者は、ペプチド・オリゴヌクレオチドCDMO市場がもたらす莫大な機会を活用するために、研究開発に投資し、戦略的パートナーシップを築き、進化する消費者の嗜好に合わせた製品を提供する必要がある。
主な特徴
ペプチド・オリゴヌクレオチドCDMO市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、ペプチドおよびオリゴヌクレオチドCDMO市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(例:ペプチドCDMO、オリゴヌクレオチドCDMO)、地域別内訳などが含まれます。
市場促進要因と課題:ペプチド・オリゴヌクレオチドCDMO市場の成長を促進する要因(政府規制、環境問題、技術進歩、消費者嗜好の変化など)を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、初期コストの高さなど、業界が直面する課題も浮き彫りにすることができる。
競合情勢:この調査レポートは、ペプチドおよびオリゴヌクレオチドCDMO市場における競争環境の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれる。また、新興プレーヤーとその潜在的な市場への影響もハイライトできます。
技術開発:調査レポートは、ペプチドおよびオリゴヌクレオチドCDMO産業における最新の技術開発を掘り下げることができます。これには、ペプチド・オリゴヌクレオチドCDMO技術の進歩、ペプチド・オリゴヌクレオチドCDMOの新規参入企業、ペプチド・オリゴヌクレオチドCDMOの新規投資、ペプチド・オリゴヌクレオチドCDMOの将来を形作るその他の技術革新が含まれます。
川下の事業者の好み:このレポートは、ペプチド・オリゴヌクレオチドCDMO市場における顧客の購買行動と採用動向を明らかにします。顧客の購買決定やペプチド・オリゴヌクレオチドCDMO製品の嗜好に影響を与える要因も含まれています。
政府の政策とインセンティブこの調査レポートは、政府の政策とインセンティブがペプチドおよびオリゴヌクレオチドCDMO市場に与える影響を分析しています。これには、ペプチドおよびオリゴヌクレオチドCDMO市場の促進を目的とした規制枠組み、補助金、税制優遇措置、その他の措置の評価が含まれる。また、市場成長促進におけるこれらの政策の有効性も評価する。
環境影響と持続可能性調査レポートは、ペプチド・オリゴヌクレオチドCDMO市場の環境影響と持続可能性の側面を評価します。
市場予測と将来展望:調査レポートでは、実施した分析に基づいて、ペプチドおよびオリゴヌクレオチドCDMO産業の市場予測と展望を提供しています。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられている。市場関係者が新たなトレンドを活用し、課題を克服し、ペプチド・オリゴヌクレオチドCDMO市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場のセグメンテーション
ペプチド・オリゴヌクレオチドCDMO市場は、タイプ別と用途別に分割される。2018年から2029年までの期間について、セグメント間の成長は、タイプ別、アプリケーション別の消費額の正確な計算と予測を提供します。
タイプ別セグメント
ペプチドCDMO
オリゴヌクレオチドCDMO
用途別セグメント
製薬・バイオテクノロジー企業
研究機関
その他
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ロンザ・グループ
サーモフィッシャーサイエンティフィック
メルク KGaA
キャタレント
ジェンスクリプト・バイオテック・コーポレーション
ポリペプチドグループ
バケムホールディングAG
無錫アプテック株式会社
味の素株式会社
レントシュラーバイオファーマSE
コーデンファーマ
ゼンケミカルズAG
アルマックグループ
ロンザカスタムマニュファクチャリング
クリエイティブペプチド
スイスカスタマイズ合成
シンゲン
ユーロジェンテック


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peptide and Oligonucleotide CDMO Market Size 2018-2029
2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Peptide and Oligonucleotide CDMO Segment by Type
2.2.1 Peptide CDMO
2.2.2 Oligonucleotide CDMO
2.3 Peptide and Oligonucleotide CDMO Market Size by Type
2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
2.4 Peptide and Oligonucleotide CDMO Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Research Institutes
2.4.3 Others
2.5 Peptide and Oligonucleotide CDMO Market Size by Application
2.5.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
3 Peptide and Oligonucleotide CDMO Market Size by Player
3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Players
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Peptide and Oligonucleotide CDMO by Regions
4.1 Peptide and Oligonucleotide CDMO Market Size by Regions (2018-2023)
4.2 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.3 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.4 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
5 Americas
5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO by Country (2018-2023)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2018-2023)
8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Peptide and Oligonucleotide CDMO Market Forecast
10.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast
10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast
10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast
10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.2.1 United States Peptide and Oligonucleotide CDMO Market Forecast
10.2.2 Canada Peptide and Oligonucleotide CDMO Market Forecast
10.2.3 Mexico Peptide and Oligonucleotide CDMO Market Forecast
10.2.4 Brazil Peptide and Oligonucleotide CDMO Market Forecast
10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast
10.3.2 Japan Peptide and Oligonucleotide CDMO Market Forecast
10.3.3 Korea Peptide and Oligonucleotide CDMO Market Forecast
10.3.4 Southeast Asia Peptide and Oligonucleotide CDMO Market Forecast
10.3.5 India Peptide and Oligonucleotide CDMO Market Forecast
10.3.6 Australia Peptide and Oligonucleotide CDMO Market Forecast
10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.4.1 Germany Peptide and Oligonucleotide CDMO Market Forecast
10.4.2 France Peptide and Oligonucleotide CDMO Market Forecast
10.4.3 UK Peptide and Oligonucleotide CDMO Market Forecast
10.4.4 Italy Peptide and Oligonucleotide CDMO Market Forecast
10.4.5 Russia Peptide and Oligonucleotide CDMO Market Forecast
10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.5.1 Egypt Peptide and Oligonucleotide CDMO Market Forecast
10.5.2 South Africa Peptide and Oligonucleotide CDMO Market Forecast
10.5.3 Israel Peptide and Oligonucleotide CDMO Market Forecast
10.5.4 Turkey Peptide and Oligonucleotide CDMO Market Forecast
10.5.5 GCC Countries Peptide and Oligonucleotide CDMO Market Forecast
10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2024-2029)
10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2024-2029)

11 Key Players Analysis
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Information
11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Lonza Group Ltd. Main Business Overview
11.1.5 Lonza Group Ltd. Latest Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Information
11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Thermo Fisher Scientific Inc. Main Business Overview
11.2.5 Thermo Fisher Scientific Inc. Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Information
11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Catalent, Inc. Main Business Overview
11.4.5 Catalent, Inc. Latest Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Information
11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Genscript Biotech Corporation Main Business Overview
11.5.5 Genscript Biotech Corporation Latest Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Information
11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Polypeptide Group Main Business Overview
11.6.5 Polypeptide Group Latest Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Information
11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Bachem Holding AG Main Business Overview
11.7.5 Bachem Holding AG Latest Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Information
11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview
11.8.5 Wuxi Apptec Co., Ltd. Latest Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Information
11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ajinomoto Co., Inc. Main Business Overview
11.9.5 Ajinomoto Co., Inc. Latest Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Information
11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Rentschler Biopharma SE Main Business Overview
11.10.5 Rentschler Biopharma SE Latest Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Information
11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Corden Pharma GmbH Main Business Overview
11.11.5 Corden Pharma GmbH Latest Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Information
11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Senn Chemicals AG Main Business Overview
11.12.5 Senn Chemicals AG Latest Developments
11.13 Almac Group
11.13.1 Almac Group Company Information
11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Almac Group Main Business Overview
11.13.5 Almac Group Latest Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Information
11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Lonza Custom Manufacturing Main Business Overview
11.14.5 Lonza Custom Manufacturing Latest Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Information
11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Creative Peptides Main Business Overview
11.15.5 Creative Peptides Latest Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Information
11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Swiss Customized Synthesis Main Business Overview
11.16.5 Swiss Customized Synthesis Latest Developments
11.17 Syngene
11.17.1 Syngene Company Information
11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered
11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Syngene Main Business Overview
11.17.5 Syngene Latest Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Information
11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Eurogentec Main Business Overview
11.18.5 Eurogentec Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our (LP Info Research) latest study, the global Peptide and Oligonucleotide CDMO market size was valued at US$ 1565.2 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Peptide and Oligonucleotide CDMO is forecast to a readjusted size of US$ 3123.4 million by 2029 with a CAGR of 10.4% during review period.
The research report highlights the growth potential of the global Peptide and Oligonucleotide CDMO market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Peptide and Oligonucleotide CDMO are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Peptide and Oligonucleotide CDMO. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Peptide and Oligonucleotide CDMO market.
Key Features:
The report on Peptide and Oligonucleotide CDMO market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Peptide and Oligonucleotide CDMO market. It may include historical data, market segmentation by Type (e.g., Peptide CDMO, Oligonucleotide CDMO), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Peptide and Oligonucleotide CDMO market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Peptide and Oligonucleotide CDMO market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Peptide and Oligonucleotide CDMO industry. This include advancements in Peptide and Oligonucleotide CDMO technology, Peptide and Oligonucleotide CDMO new entrants, Peptide and Oligonucleotide CDMO new investment, and other innovations that are shaping the future of Peptide and Oligonucleotide CDMO.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Peptide and Oligonucleotide CDMO market. It includes factors influencing customer ' purchasing decisions, preferences for Peptide and Oligonucleotide CDMO product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Peptide and Oligonucleotide CDMO market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Peptide and Oligonucleotide CDMO market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Peptide and Oligonucleotide CDMO market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Peptide and Oligonucleotide CDMO industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Peptide and Oligonucleotide CDMO market.
Market Segmentation:
Peptide and Oligonucleotide CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Peptide CDMO
Oligonucleotide CDMO
Segmentation by application
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza Group Ltd.
Thermo Fisher Scientific Inc.
Merck KGaA
Catalent, Inc.
Genscript Biotech Corporation
Polypeptide Group
Bachem Holding AG
Wuxi Apptec Co., Ltd.
Ajinomoto Co., Inc.
Rentschler Biopharma SE
Corden Pharma GmbH
Senn Chemicals AG
Almac Group
Lonza Custom Manufacturing
Creative Peptides
Swiss Customized Synthesis
Syngene
Eurogentec



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peptide and Oligonucleotide CDMO Market Size 2018-2029
2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Peptide and Oligonucleotide CDMO Segment by Type
2.2.1 Peptide CDMO
2.2.2 Oligonucleotide CDMO
2.3 Peptide and Oligonucleotide CDMO Market Size by Type
2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
2.4 Peptide and Oligonucleotide CDMO Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Research Institutes
2.4.3 Others
2.5 Peptide and Oligonucleotide CDMO Market Size by Application
2.5.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
3 Peptide and Oligonucleotide CDMO Market Size by Player
3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Players
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Peptide and Oligonucleotide CDMO by Regions
4.1 Peptide and Oligonucleotide CDMO Market Size by Regions (2018-2023)
4.2 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.3 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.4 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
5 Americas
5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO by Country (2018-2023)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2018-2023)
8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Peptide and Oligonucleotide CDMO Market Forecast
10.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast
10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast
10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast
10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.2.1 United States Peptide and Oligonucleotide CDMO Market Forecast
10.2.2 Canada Peptide and Oligonucleotide CDMO Market Forecast
10.2.3 Mexico Peptide and Oligonucleotide CDMO Market Forecast
10.2.4 Brazil Peptide and Oligonucleotide CDMO Market Forecast
10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast
10.3.2 Japan Peptide and Oligonucleotide CDMO Market Forecast
10.3.3 Korea Peptide and Oligonucleotide CDMO Market Forecast
10.3.4 Southeast Asia Peptide and Oligonucleotide CDMO Market Forecast
10.3.5 India Peptide and Oligonucleotide CDMO Market Forecast
10.3.6 Australia Peptide and Oligonucleotide CDMO Market Forecast
10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.4.1 Germany Peptide and Oligonucleotide CDMO Market Forecast
10.4.2 France Peptide and Oligonucleotide CDMO Market Forecast
10.4.3 UK Peptide and Oligonucleotide CDMO Market Forecast
10.4.4 Italy Peptide and Oligonucleotide CDMO Market Forecast
10.4.5 Russia Peptide and Oligonucleotide CDMO Market Forecast
10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.5.1 Egypt Peptide and Oligonucleotide CDMO Market Forecast
10.5.2 South Africa Peptide and Oligonucleotide CDMO Market Forecast
10.5.3 Israel Peptide and Oligonucleotide CDMO Market Forecast
10.5.4 Turkey Peptide and Oligonucleotide CDMO Market Forecast
10.5.5 GCC Countries Peptide and Oligonucleotide CDMO Market Forecast
10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2024-2029)
10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2024-2029)

11 Key Players Analysis
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Information
11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Lonza Group Ltd. Main Business Overview
11.1.5 Lonza Group Ltd. Latest Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Information
11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Thermo Fisher Scientific Inc. Main Business Overview
11.2.5 Thermo Fisher Scientific Inc. Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Information
11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Catalent, Inc. Main Business Overview
11.4.5 Catalent, Inc. Latest Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Information
11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Genscript Biotech Corporation Main Business Overview
11.5.5 Genscript Biotech Corporation Latest Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Information
11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Polypeptide Group Main Business Overview
11.6.5 Polypeptide Group Latest Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Information
11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Bachem Holding AG Main Business Overview
11.7.5 Bachem Holding AG Latest Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Information
11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview
11.8.5 Wuxi Apptec Co., Ltd. Latest Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Information
11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ajinomoto Co., Inc. Main Business Overview
11.9.5 Ajinomoto Co., Inc. Latest Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Information
11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Rentschler Biopharma SE Main Business Overview
11.10.5 Rentschler Biopharma SE Latest Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Information
11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Corden Pharma GmbH Main Business Overview
11.11.5 Corden Pharma GmbH Latest Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Information
11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Senn Chemicals AG Main Business Overview
11.12.5 Senn Chemicals AG Latest Developments
11.13 Almac Group
11.13.1 Almac Group Company Information
11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Almac Group Main Business Overview
11.13.5 Almac Group Latest Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Information
11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Lonza Custom Manufacturing Main Business Overview
11.14.5 Lonza Custom Manufacturing Latest Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Information
11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Creative Peptides Main Business Overview
11.15.5 Creative Peptides Latest Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Information
11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Swiss Customized Synthesis Main Business Overview
11.16.5 Swiss Customized Synthesis Latest Developments
11.17 Syngene
11.17.1 Syngene Company Information
11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered
11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Syngene Main Business Overview
11.17.5 Syngene Latest Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Information
11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Eurogentec Main Business Overview
11.18.5 Eurogentec Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/07 10:27

155.63 円

167.26 円

203.27 円

ページTOPに戻る